Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Schwaab, Juliana ^a   Horisberger, Karoline ^a   Ströbel, Philipp ^a   Bohn, Beatrice ^a   Gencer, Deniz ^a   Kähler, Georg ^a   Kienle, Peter ^a   Post, Stefan ^a   Wenz, Frederik ^a   Hofmann, Wolf Karsten ^a   Hofheinz, Ralf Dieter ^a   Erben, Philipp ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Hypoxia; Radiochemotherapy; Rectal cancer; TKTL1; VEGFR 1 2

Indexed keywords

CAPECITABINE; CETUXIMAB; GENE PRODUCT; IRINOTECAN; TRANSKETOLASE LIKE 1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY; TKTL1 PROTEIN, HUMAN; TRANSKETOLASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; RECTUM CANCER; TRANKETOLASE LIKE GENE 1; TREATMENT RESPONSE; TUMOR BIOPSY; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; BIOSYNTHESIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUM TUMOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECTAL NEOPLASMS; STATISTICS, NONPARAMETRIC; TRANSKETOLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80051800563     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-363     Document Type: Article

References (42)

1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(17):1731-1740. 10.1056/NEJMoa040694, 15496622.
2. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, Wenz F, Hochhaus A, Post S, Willeke F, et al. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009, 20(6):519-524. 10.1097/CAD.0b013e32832b53ff, 19436196.
3. Marquardt F, Rodel F, Capalbo G, Weiss C, Rodel C. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 2009, 185(6):371-378. 10.1007/s00066-009-1936-5, 19506820.
4. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82(1):4-6. 10.1093/jnci/82.1.4, 1688381.
5. Giralt J, Navalpotro B, Hermosilla E, de Torres I, Espin E, Reyes V, Cerezo L, de las Heras M, Ramon y Cajal S, Armengol M, et al. Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 2006, 71(5-6):312-319. 10.1159/000107105, 17687192.
6. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010, 32(3):437-453. 10.1016/j.clinthera.2010.03.012, 20399983.
7. Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK, Metcalf CA, Shakespeare WC, Hicklin DJ, Ellis LM, et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006, 94(11):1710-1717. 2361330, 16685275.
8. Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, Hayashi S, Jass JR. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008, 98(2):450-456. 10.1038/sj.bjc.6604172, 2361457, 18182986.
9. Andre T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, Prevot S, Parc R, Gespach C, Chastre E. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000, 86(2):174-181. 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.0.CO;2-E, 10738243.
10. Carlomagno C, Pepe S, D'Armiento FP, D'Armiento M, Cannella L, De Stefano A, Crispo A, Giordano M, De Placido S. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Oncology 2010, 78(5-6):369-375. 10.1159/000320464, 20798559.
11. Negri FV, Campanini N, Camisa R, Pucci F, Bui S, Ceccon G, Martinelli R, Fumagalli M, Losardo PL, Crafa P, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008, 98(1):143-147. 10.1038/sj.bjc.6604131, 2359706, 18087284.
12. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Carcinomzelle. Biochem Z 1924, 152:309-344.
13. Coy JF, Dressler D, Wilde J, Schubert P. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 2005, 51(5-6):257-273.
14. Hu LH, Yang JH, Zhang DT, Zhang S, Wang L, Cai PC, Zheng JF, Huang JS. The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs 2007, 18(4):427-433. 10.1097/CAD.0b013e328013d99e, 17351395.
15. Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, Alken P, Coy JF. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 2008, 122(11):2422-2428. 10.1002/ijc.23403, 18302154.
16. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006, 94(4):578-585. 10.1038/sj.bjc.6602962, 2361175, 16465194.
17. Xu X, Zur Hausen A, Coy JF, Lochelt M. Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 2009, 124(6):1330-1337. 10.1002/ijc.24078, 19065656.
18. Zhang S, Yue JX, Yang JH, Cai PC, Kong WJ. Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma: a potential therapeutic target in nasopharyngeal carcinoma. Cancer Biol Ther 2008, 7(4):517-522. 10.4161/cbt.7.4.5479, 18296915.
19. Hofheinz RD, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kahler G, Dinter D, Grobholz R, Heeger S, Post S, et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006, 66(5):1384-1390. 10.1016/j.ijrobp.2006.07.005, 16979839.
20. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Strobel P, Erben P, Woernle C, Dinter D, Kahler G, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009, 74(5):1487-1493. 10.1016/j.ijrobp.2008.10.014, 19131187.
21. Schmiegel W, Adler G, Fruhmorgen P, Folsch U, Graeven U, Layer P, Petrasch S, Porschen R, Pox C, Sauerbruch T, et al. Colorectal carcinoma: prevention and early detection in an asymptomatic population--prevention in patients at risk--endoscopic diagnosis, therapy and after-care of polyps and carcinomas. German Society of Digestive and Metabolic Diseases/Study Group for Gastrointestinal Oncology. Z Gastroenterol 2000, 38(1):49-75. 10.1055/s-2000-14850, 10689748.
22. Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000, 124(7):1016-1025.
23. (JSCCR) JSfCotCaR Japanese classification of colorectal carcinoma, 1st English ed. 1997, (JSCCR) JSfCotCaR.
24. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002, 53(3):664-674. 10.1016/S0360-3016(02)02764-5, 12062610.
25. Erben P, Horisberger K, Muessle B, Muller MC, Treschl A, Ernst T, Kahler G, Strobel P, Wenz F, Kienle P, et al. mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2008, 72(5):1544-1550. 10.1016/j.ijrobp.2008.08.013, 19028276.
26. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17(6):1013-1034. 10.1038/sj.leu.2402922, 12764363.
27. Muller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T, Ernst T, Lauber S, Kruth J, Hehlmann R, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008, 22(1):96-102. 10.1038/sj.leu.2404983, 17943168.
28. Erben P, Strobel P, Horisberger K, Popa J, Bohn B, Hanfstein B, Kahler G, Kienle P, Post S, Wenz F, et al. KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2010,
29. Horisberger K, Erben P, Strobel P, Bohn B, Hahn M, Kahler G, Wenz F, Hochhaus A, Post S, Willeke F, et al. Annexin and survivin in locally advanced rectal cancer: indicators of resistance to preoperative chemoradiotherapy?. Onkologie 2010, 33(8-9):439-444. 10.1159/000318145, 20838059.
30. Postovit LM, Adams MA, Lash GE, Heaton JP, Graham CH. Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. J Biol Chem 2002, 277(38):35730-35737. 10.1074/jbc.M204529200, 12107174.
31. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 1996, 2(7):1151-1154.
32. Staiger WI, Coy JF, Grobholz R, Hofheinz RD, Lukan N, Post S, Schwarzbach MH, Willeke F. Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep 2006, 16(4):657-661.
33. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 1997, 57(19):4242-4248.
34. Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, Park JG. Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009, 30(12):2182-2192. 10.1002/elps.200800806, 19582719.
35. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005, 65(2):613-621.
36. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9(6):425-434. 10.1016/j.ccr.2006.04.023, 16766262.
37. Comin-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, Trebukhina R, Petushok N, Lee WN, Boros LG, Cascante M. The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem 2001, 268(15):4177-4182. 10.1046/j.1432-1327.2001.02329.x, 11488910.
38. Mathupala SP, Colen CB, Parajuli P, Sloan AE. Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr 2007, 39(1):73-77. 10.1007/s10863-006-9062-x, 17354062.
39. Chacko SM, Ahmed S, Selvendiran K, Kuppusamy ML, Khan M, Kuppusamy P. Hypoxic preconditioning induces the expression of pro-survival and pro-angiogenic markers in mesenchymal stem cells. Am J Physiol Cell Physiol 2010,
40. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269(43):26988-26995.
41. Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007, 68(5):1455-1461. 10.1016/j.ijrobp.2007.02.018, 17445998.
42. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136(5):823-837. 10.1016/j.cell.2009.02.024, 2894612, 19269363.